Crocetin has been shown to increase dopamine and its metabolites, to inhibit alpha-synuclein aggregation and promote alpha-synuclein fibril dissociation, with significant potential in Parkinson and other αS aggregation related diseases (Ahmad et al., 2005; Inoue et al., 2017). Here, SNCA is linked to Parkinsonism.